Focused & Specialized

Clinical trial sponsors working in oncology, hematology, IBD, infectious diseases, multiple sclerosis, and many rare diseases rely on PSI’s guidance and experience, knowing we’re specialized and committed to delivering some of the most complex clinical projects in the industry.

2000+

employees in more than 60+ countries are dedicated to your success

Therapeutic areas

Inflammatory Bowel Diseases (IBD)

Crohns’ Disease, Ulcerative Colitis, and other IBDs.

Oncology

Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, and other Oncology indications.

Hematology

Multiple Myeloma, Lymphomas, Leukemias, and other oncohematological indications.

Infectious Diseases

Antimicrobial and Antifungal infections and other ID.

Multiple Sclerosis

Multiple Sclerosis, Spasticity, and other neurological indications.

Rare Diseases

Hemophilia A & B, Von Willebrand Disease, Thrombocytopenia, Polycythemia Vera, Paroxysmal Nocturnal Hemoglobinuria (PNH).

Meet the global clinical research organization ranked No. 1

Ranked #1 Global CRO by Investigators Worldwide. CenterWatch 2015-2017

The PSI Advantage

In 2021, PSI CRO has again received CRO Leadership Awards in five categories, including Compatibility, Expertise, Quality, Reliability, and Capabilities across two respondent groups (Overall and Small Pharma). In the Expertise category, PSI CRO is recognized as a Champion in the Leadership Awards. The CRO Leadership Awards are presented by Life Sciences Leader based on research conducted by ISR reports. The awards recognize CROs that are voted by sponsors to meet or exceed expectations.

PSI was flexible to meet the various challenges in clinical trial conduct. The rapid enrollment of patients and the quick study close out allowed on-time study completion.

Chief Medical Officer